title: Chemotherapy in the management of infantile fibrosarcoma.
abstract: Infantile fibrosarcoma (IF) has traditionally been treated with surgery, which may have considerable morbidity. Chemotherapy has been suggested in order to reduce the need for extensive surgery. Nine children with histologically confirmed IF who received chemotherapy are described. Six children were treated with chemotherapy initially, two following conservative surgery, and one following recurrence after surgery. All received vincristine (V) and actinomycin D (A), and six received additional drugs including ifosfamide (I), cyclophosphamide (C), adriamycin (Ad), etoposide (E), and cisplatinum (CDDP). Objective responses were achieved in eight: three responded completely (CR), two responded partially (PR), which allowed conservative surgery, one had stable disease, one had an initial PR, but subsequently had tumour recurrence 1 month after cessation of treatment, necessitating further surgery and chemotherapy, and one had an initial PR but died following local and regional metastases. One child had no response to chemotherapy but is alive with stable residual disease. Thus, five of nine children achieved a CR--three with chemotherapy alone. With the inclusion of chemotherapy as part of their treatment, five children, for whom curative surgery may have resulted in amputation, remain alive with limbs intact. Chemotherapy including V and A should be given to infants with fibrosarcoma in whom curative surgery would be mutilating.
authors.affiliation: Department of Child Health, University of Newcastle Upon Tyne, United Kingdom.
authors.forename: J A
authors.initials: JA
authors.lastname: Kynaston
authors.forename: A J
authors.initials: AJ
authors.lastname: Malcolm
authors.forename: A W
authors.initials: AW
authors.lastname: Craft
authors.forename: S M
authors.initials: SM
authors.lastname: Davies
authors.forename: P H
authors.initials: PH
authors.lastname: Jones
authors.forename: D J
authors.initials: DJ
authors.lastname: King
authors.forename: C D
authors.initials: CD
authors.lastname: Mitchell
authors.forename: A
authors.initials: A
authors.lastname: Oakhill
authors.forename: C A
authors.initials: CA
authors.lastname: Stiller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007223:Infant; D007231:Infant, Newborn; D007621:Karyotyping; D007866:Leg; D008297:Male; D012074:Remission Induction; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D007069:Ifosfamide